Hemostemix Inc. announced a presentation by Dr. William Shankle on vascular cognitive impairment and the clinical trial of VesCell™, an autologous stem cell therapy aimed at treating vascular dementia. VesCell™ promotes blood vessel regeneration and repair, addressing a major unmet need as no FDA-approved treatments currently exist for vascular cognitive impairment. The clinical trial, now enrolling participants, seeks to evaluate VesCell™'s safety and efficacy. This development could offer new hope for millions affected by vascular dementia and related cognitive disorders.
Nvidia, a leading semiconductor and AI company, is expected to report strong Q2 fiscal 2027 earnings on August 26, with analysts anticipating revenue around $91.9 billion and adjusted earnings of $2.08 per share. RBC Capital maintains an "Outperform"...
Deere & Company reported third-quarter earnings per share of $5.10, surpassing analyst expectations of $4.71, and revenue of $12.61 billion, exceeding estimates of $10.81 billion. The growth was mainly driven by strong performance in the construction...
Piper Sandler raised AbbVie's price target to $303, indicating a potential 13.92% upside from its current price of $265.97. This reflects positive expectations for the biopharmaceutical company's future performance. Institutional investors like J. M....
BTIG reaffirmed its 'Buy' rating for Glaukos and increased the price target to $202, citing strong sales growth. U.S. glaucoma sales rose 64% to $118.5 million, driven by the iDose TR product, while Corneal Health revenues grew 48% to $30.4 million, ...
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
